{"id":75758,"date":"2026-08-21T12:08:33","date_gmt":"2026-08-21T04:08:33","guid":{"rendered":"https:\/\/flcube.com\/?p=75758"},"modified":"2026-08-21T12:08:34","modified_gmt":"2026-08-21T04:08:34","slug":"pharmaron-posts-17-9-first-half-revenue-growth-as-cro-demand-rebounds-cdmo-and-all-core-segments-expand","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=75758","title":{"rendered":"Pharmaron Posts 17.9% First\u2011Half Revenue Growth as CRO Demand Rebounds; CDMO and All Core Segments Expand"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Pharmaron Beijing Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/3759:HKG\">HKG: 3759<\/a>), a leading integrated <strong>CRO<\/strong> and <strong>CDMO<\/strong> service provider, announced its unaudited interim results for the six months ended 30 June 2026. The company reported total revenue of approximately <strong>RMB 7.60 billion<\/strong>, a <strong>17.9% year\u2011over\u2011year increase<\/strong>, with profit attributable to owners of the parent rising <strong>7.0%<\/strong> to roughly <strong>RMB 750 million<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-h1-2026-financial-highlights\" class=\"wp-block-heading\">H1 2026 Financial Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>H1 2026<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>~RMB 7.60 billion<\/td><td><strong>+17.9 %<\/strong><\/td><\/tr><tr><td><strong>Profit Attributable to Owners<\/strong><\/td><td>~RMB 750 million<\/td><td><strong>+7.0 %<\/strong><\/td><\/tr><tr><td><strong>New Orders Booked<\/strong><\/td><td>Surge &gt;30 % vs. prior\u2011year H1<\/td><td>\u2013<\/td><\/tr><tr><td><strong>FY2026 Revenue Guidance<\/strong><\/td><td>Growth of ~15 %\u201320 %<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-segment-performance-all-three-core-businesses-grow\" class=\"wp-block-heading\">Segment Performance \u2013 All Three Core Businesses Grow<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Business Segment<\/th><th>H1 2026 Revenue<\/th><th>Share of Total<\/th><\/tr><\/thead><tbody><tr><td><strong>Laboratory Services<\/strong><\/td><td>RMB 4.63 billion<\/td><td>~61 %<\/td><\/tr><tr><td><strong>CDMO Services<\/strong><\/td><td>RMB 1.88 billion<\/td><td>~25 %<\/td><\/tr><tr><td><strong>Clinical Research Services<\/strong><\/td><td>RMB 1.07 billion<\/td><td>~14 %<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">All three core business segments delivered growth during the period, underscoring the resilience of <strong>Pharmaron&#8217;s<\/strong> integrated <strong>CRO\u2011CDMO<\/strong> platform spanning drug discovery through commercial manufacturing.<\/p>\n\n\n\n<h2 id=\"h-order-momentum-amp-management-outlook\" class=\"wp-block-heading\">Order Momentum &amp; Management Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>New Orders:<\/strong> Bookings surged over <strong>30%<\/strong> year\u2011over\u2011year in the first half, signaling strengthening demand across the company&#8217;s service lines<\/li>\n\n\n\n<li><strong>Guidance:<\/strong> Based on current order momentum and business trends, management expects full\u2011year 2026 revenue growth of approximately <strong>15%\u201320%<\/strong><\/li>\n\n\n\n<li><strong>Implication:<\/strong> The guidance implies sustained acceleration in the second half, supported by the expanding order backlog<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CRO Sector Recovery:<\/strong> The results reinforce signs of a broader rebound in outsourced R&amp;D spending, as biopharma clients resume pipeline investment following the funding downcycle of recent years<\/li>\n\n\n\n<li><strong>Integrated Platform Edge:<\/strong> <strong>Pharmaron&#8217;s<\/strong> ability to grow across Laboratory Services, <strong>CDMO<\/strong>, and Clinical Research simultaneously highlights the appeal of one\u2011stop providers to cost\u2011conscious sponsors<\/li>\n\n\n\n<li><strong>Profit vs. Revenue Dynamics:<\/strong> Profit growth of 7.0% lagged revenue expansion of 17.9%, suggesting margin pressure or investment spending \u2014 a watch item for investors assessing second\u2011half profitability<\/li>\n\n\n\n<li><strong>Visibility:<\/strong> With new orders up more than 30% and explicit full\u2011year guidance, <strong>Pharmaron<\/strong> offers rare forward visibility in the <strong>CRO<\/strong> sector<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Pharmaron&#8217;s revenue guidance, order momentum, and business outlook for 2026. Actual results may differ due to risks including client spending patterns, geopolitical and regulatory developments, and competitive pricing in the CRO and CDMO markets.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082001534_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026082001534_c.\"><\/object><a id=\"wp-block-file--media-19c8f20a-d455-4e7e-b299-d57b597d425e\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082001534_c.pdf\">2026082001534_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082001534_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-19c8f20a-d455-4e7e-b299-d57b597d425e\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Pharmaron Beijing Co., Ltd. (HKG: 3759), a leading integrated CRO and CDMO service provider, announced&#8230;<\/p>\n","protected":false},"author":1,"featured_media":75760,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[19,27,1501,768],"class_list":["post-75758","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-cro-cmo-cdmo","tag-finanical-reports","tag-hkg-3759","tag-pharmaron"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pharmaron Posts 17.9% First\u2011Half Revenue Growth as CRO Demand Rebounds; CDMO and All Core Segments Expand - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Pharmaron Beijing Co., Ltd. (HKG: 3759), a leading integrated CRO and CDMO service provider, announced its unaudited interim results for the six months ended 30 June 2026. The company reported total revenue of approximately RMB 7.60 billion, a 17.9% year\u2011over\u2011year increase, with profit attributable to owners of the parent rising 7.0% to roughly RMB 750 million.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=75758\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharmaron Posts 17.9% First\u2011Half Revenue Growth as CRO Demand Rebounds; CDMO and All Core Segments Expand\" \/>\n<meta property=\"og:description\" content=\"Pharmaron Beijing Co., Ltd. (HKG: 3759), a leading integrated CRO and CDMO service provider, announced its unaudited interim results for the six months ended 30 June 2026. The company reported total revenue of approximately RMB 7.60 billion, a 17.9% year\u2011over\u2011year increase, with profit attributable to owners of the parent rising 7.0% to roughly RMB 750 million.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=75758\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-21T04:08:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-21T04:08:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2102.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75758#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75758\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pharmaron Posts 17.9% First\u2011Half Revenue Growth as CRO Demand Rebounds; CDMO and All Core Segments Expand\",\"datePublished\":\"2026-08-21T04:08:33+00:00\",\"dateModified\":\"2026-08-21T04:08:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75758\"},\"wordCount\":368,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75758#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2102.webp\",\"keywords\":[\"CRO \\\/ CMO \\\/ CDMO\",\"Finanical Reports\",\"HKG: 3759\",\"Pharmaron\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75758#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75758\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=75758\",\"name\":\"Pharmaron Posts 17.9% First\u2011Half Revenue Growth as CRO Demand Rebounds; CDMO and All Core Segments Expand - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75758#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75758#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2102.webp\",\"datePublished\":\"2026-08-21T04:08:33+00:00\",\"dateModified\":\"2026-08-21T04:08:34+00:00\",\"description\":\"Pharmaron Beijing Co., Ltd. (HKG: 3759), a leading integrated CRO and CDMO service provider, announced its unaudited interim results for the six months ended 30 June 2026. The company reported total revenue of approximately RMB 7.60 billion, a 17.9% year\u2011over\u2011year increase, with profit attributable to owners of the parent rising 7.0% to roughly RMB 750 million.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75758#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75758\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75758#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2102.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2102.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pharmaron Posts 17.9% First\u2011Half Revenue Growth as CRO Demand Rebounds; CDMO and All Core Segments Expand\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75758#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharmaron Posts 17.9% First\u2011Half Revenue Growth as CRO Demand Rebounds; CDMO and All Core Segments Expand\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharmaron Posts 17.9% First\u2011Half Revenue Growth as CRO Demand Rebounds; CDMO and All Core Segments Expand - Insight, China&#039;s Pharmaceutical Industry","description":"Pharmaron Beijing Co., Ltd. (HKG: 3759), a leading integrated CRO and CDMO service provider, announced its unaudited interim results for the six months ended 30 June 2026. The company reported total revenue of approximately RMB 7.60 billion, a 17.9% year\u2011over\u2011year increase, with profit attributable to owners of the parent rising 7.0% to roughly RMB 750 million.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=75758","og_locale":"en_US","og_type":"article","og_title":"Pharmaron Posts 17.9% First\u2011Half Revenue Growth as CRO Demand Rebounds; CDMO and All Core Segments Expand","og_description":"Pharmaron Beijing Co., Ltd. (HKG: 3759), a leading integrated CRO and CDMO service provider, announced its unaudited interim results for the six months ended 30 June 2026. The company reported total revenue of approximately RMB 7.60 billion, a 17.9% year\u2011over\u2011year increase, with profit attributable to owners of the parent rising 7.0% to roughly RMB 750 million.","og_url":"https:\/\/flcube.com\/?p=75758","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-21T04:08:33+00:00","article_modified_time":"2026-08-21T04:08:34+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2102.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=75758#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=75758"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pharmaron Posts 17.9% First\u2011Half Revenue Growth as CRO Demand Rebounds; CDMO and All Core Segments Expand","datePublished":"2026-08-21T04:08:33+00:00","dateModified":"2026-08-21T04:08:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=75758"},"wordCount":368,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=75758#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2102.webp","keywords":["CRO \/ CMO \/ CDMO","Finanical Reports","HKG: 3759","Pharmaron"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=75758#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=75758","url":"https:\/\/flcube.com\/?p=75758","name":"Pharmaron Posts 17.9% First\u2011Half Revenue Growth as CRO Demand Rebounds; CDMO and All Core Segments Expand - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=75758#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=75758#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2102.webp","datePublished":"2026-08-21T04:08:33+00:00","dateModified":"2026-08-21T04:08:34+00:00","description":"Pharmaron Beijing Co., Ltd. (HKG: 3759), a leading integrated CRO and CDMO service provider, announced its unaudited interim results for the six months ended 30 June 2026. The company reported total revenue of approximately RMB 7.60 billion, a 17.9% year\u2011over\u2011year increase, with profit attributable to owners of the parent rising 7.0% to roughly RMB 750 million.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=75758#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=75758"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=75758#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2102.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2102.webp","width":1080,"height":608,"caption":"Pharmaron Posts 17.9% First\u2011Half Revenue Growth as CRO Demand Rebounds; CDMO and All Core Segments Expand"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=75758#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pharmaron Posts 17.9% First\u2011Half Revenue Growth as CRO Demand Rebounds; CDMO and All Core Segments Expand"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2102.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75758","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=75758"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75758\/revisions"}],"predecessor-version":[{"id":75761,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75758\/revisions\/75761"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/75760"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=75758"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=75758"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=75758"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}